AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26375690 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study 24200186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 50
Study 24200186 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding
Number of subjects: 50
Study 24200186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NG and oral feeding
Number of subjects: 50
Study 21611944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation (BEC)
Number of subjects: 30
Study 21611944 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 30
Study 19147399 — intervention group
Group type: EXPERIMENTAL
Intervention: autotitrating pressure relief CPAP (PR‐APAP)
Number of subjects: 11
Study 19147399 — intervention group
Group type: EXPERIMENTAL
Intervention: autotitrating CPAP (APAP)
Number of subjects: 11
Study 16689375 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker carvedilol (5 mg/day)
Number of subjects: 0
Study 16689375 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker carvedilol (20 mg/day)
Number of subjects: 0
Study 16689375 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker carvedilol (under 2.5 mg/day)
Number of subjects: 0
Study 15220768 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 microg/ml
Number of subjects: 60
Study 15220768 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 3 mg/ml
Number of subjects: 60
Study 11427407 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index < or =20.3 in men
Number of subjects: 0
Study 11427407 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index < or =18.5 in women
Number of subjects: 0
Study 11427407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass < or =6% in men
Number of subjects: 0
Study 11427407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass < or =18% in women
Number of subjects: 0
Study 11427407 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm muscle circumference
Number of subjects: 0
Study 9241342 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge Whitacre needle
Number of subjects: 200
Study 9241342 — intervention group
Group type: COMPARATOR
Intervention: 27-gauge Quincke needle
Number of subjects: 200
Study 8306010 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF treatment (1 or more cycles)
Number of subjects: 399
Study 8306010 — intervention group
Group type: COMPARATOR
Intervention: Control group (awaiting IVF treatment)
Number of subjects: 399
Study 3734775 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine
Number of subjects: 42
Study 3734775 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 42
Study 31228228 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of automatically calculated birthweight centiles (2015)
Number of subjects: 400
Study 31228228 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent care to the guideline (2015)
Number of subjects: 400
Study 31228228 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent care to the guideline (2011)
Number of subjects: 400
Study 30342464 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based, low intensity physical exercise program
Number of subjects: 115
Study 30342464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 27842499 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of remifentanil (0.3‐μg/kg/min for 5 min followed by 0.1‐μg/kg/min)
Number of subjects: 107
Study 27842499 — intervention group
Group type: COMPARATOR
Intervention: Two bolus injections of remifentanil (first bolus of 0.4 μg/kg and second bolus of 0.6 μg/kg after 3 min) and 0.1 μg/kg/min remifentanil
Number of subjects: 107
Study 24447332 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated TIMP-1
Number of subjects: 0
Study 24447332 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated MMP-2
Number of subjects: 0
Study 24447332 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated MMP-1
Number of subjects: 0
Study 24447332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (resistant)
Number of subjects: 0
Study 24447332 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 22472914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar graphs
Number of subjects: 106
Study 22472914 — intervention group
Group type: COMPARATOR
Intervention: Tables
Number of subjects: 106
Study 20386122 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment protocol (4RM parallel back half-squat)
Number of subjects: 12
Study 20386122 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (no 4RM back-squat)
Number of subjects: 12
Study 18247155 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 320
Study 18247155 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telephonic reminder
Number of subjects: 320
Study 18247155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder)
Number of subjects: 320
Study 16641287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 with biovector
Number of subjects: 100
Study 16641287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 without biovector
Number of subjects: 100
Study 16641287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccine with 15 microg hemagglutinin and MF59 adjuvant
Number of subjects: 100
Study 16641287 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (saline solution)
Number of subjects: 100
Study 14710766 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (bilaminar surgical technique with modified connective tissue graft)
Number of subjects: 15
Study 14710766 — intervention group
Group type: COMPARATOR
Intervention: Control group (bilaminar surgical technique with standard connective tissue graft)
Number of subjects: 15
Study 10720584 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 112
Study 10720584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 8667183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.125 mg/70 kg i.v.)
Number of subjects: 2
Study 8667183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.25 mg/70 kg i.v.)
Number of subjects: 2
Study 8667183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (1 mg/70 kg i.v.)
Number of subjects: 2
Study 8667183 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (2 mg/70 kg i.v.)
Number of subjects: 2
Study 8667183 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 2
Study 8667183 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.)
Number of subjects: 2
Study 1641432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost subsidy, mammography van, and tailored health education interventions
Number of subjects: 412
Study 1641432 — intervention group
Group type: COMPARATOR
Intervention: Cost subsidy alone (Control)
Number of subjects: 412
Study 1641432 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at the educational presentation (within experimental group)
Number of subjects: 412
Study 6197239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 136
Study 30726224 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose sulfadoxine-pyrimethamine (SP) and 3 doses of amodiaquine (AQ) every three months
Number of subjects: 206
Study 29024410 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (OD) for 8 weeks
Number of subjects: 60
Study 29024410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29024410 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg OD for 8 weeks
Number of subjects: 60
Study 26743775 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg glucagon
Number of subjects: 8
Study 26743775 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg glucagon
Number of subjects: 8
Study 26743775 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 µg glucagon
Number of subjects: 8
Study 26743775 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 24601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Managers choosing a new alternative versus familiar alternative
Number of subjects: 0
Study 24601909 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk takers versus low risk takers
Number of subjects: 0
Study 24601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision makers opposing others' advice by choosing high risk option
Number of subjects: 0
Study 22974886 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/d; group A)
Number of subjects: 44
Study 22974886 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (800 mg loading dose and thereafter 400 mg/d; group B)
Number of subjects: 44
Study 20102150 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 30 mg/kg
Number of subjects: 0
Study 20102150 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 50 mg/kg
Number of subjects: 0
Study 20102150 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 0.1 mg/kg, i.v.
Number of subjects: 0
Study 20102150 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 1.0 mg/kg, i.v.
Number of subjects: 0
Study 16935912 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 2 mg/kg during double-blind phase
Number of subjects: 121
Study 16935912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 16935912 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg during LTE
Number of subjects: 121
Study 16935912 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept and etanercept
Number of subjects: 121
Study 16935912 — intervention group
Group type: COMPARATOR
Intervention: Placebo and etanercept
Number of subjects: 121
Study 16970088 — intervention group
Group type: EXPERIMENTAL
Intervention: ETR plus FSH
Number of subjects: 66
Study 16970088 — intervention group
Group type: COMPARATOR
Intervention: FSH alone
Number of subjects: 66
Study 12211346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent decision support systems
Number of subjects: 0
Study 12211346 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10474785 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 8714425 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 15 mg daily for 7 weeks
Number of subjects: 31
Study 8714425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8714425 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 15 mg daily
Number of subjects: 31
Study 1927727 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme emphasizing healthy diet, non-smoking encouragement, and physical activity for 281 pupils.
Number of subjects: 521
Study 1927727 — intervention group
Group type: COMPARATOR
Intervention: Control group (240 pupils who did not participate in the programme).
Number of subjects: 521
Study 6336944 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoid therapy
Number of subjects: 8
Study 6336944 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically involved psoriatic epidermis
Number of subjects: 8
Study 6336944 — intervention group
Group type: COMPARATOR
Intervention: Uninvolved skin of the same patients
Number of subjects: 8
Study 31640921 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) therapy
Number of subjects: 21
Study 31640921 — intervention group
Group type: COMPARATOR
Intervention: Rigid immobilization
Number of subjects: 21
Study 31517964 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-linked savings accounts with 1000 Kenya shillings (US 10) and weekly lottery-based rewards contingent on growth in savings balance
Number of subjects: 300
Study 31517964 — intervention group
Group type: COMPARATOR
Intervention: Standard interest savings accounts
Number of subjects: 300
Study 27695925 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial method
Number of subjects: 166
Study 27695925 — intervention group
Group type: COMPARATOR
Intervention: Noncoaxial method
Number of subjects: 166
Study 26523919 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg twice daily
Number of subjects: 1254
Study 26523919 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg twice daily
Number of subjects: 1254
Study 26523919 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg twice daily
Number of subjects: 1254
Study 26523919 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate 1 mg/d
Number of subjects: 1254
Study 26523919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1254
Study 24680227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT), 16-20 sessions over 12-14 weeks
Number of subjects: 473
Study 24680227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 473
Study 22976847 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy (TNE)
Number of subjects: 397
Study 22976847 — intervention group
Group type: COMPARATOR
Intervention: Sedated endoscopy (SES)
Number of subjects: 397
Study 22976847 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy (CES)
Number of subjects: 397
Study 19574169 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary protein measurement
Number of subjects: 200
Study 19574169 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary calcium measurement
Number of subjects: 200
Study 17888019 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement in extraction sockets exhibiting periapical pathology (test group)
Number of subjects: 34
Study 17888019 — intervention group
Group type: COMPARATOR
Intervention: Immediate implant placement in extraction sockets without periapical pathology (control group)
Number of subjects: 34
Study 15130377 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) alone, Group A
Number of subjects: 96
Study 15130377 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone alone, Group B
Number of subjects: 96
Study 15130377 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) and rosiglitazone in combination, Group C
Number of subjects: 96
Study 11404757 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer + adhesive group (PA)
Number of subjects: 80
Study 11404757 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer‐only group (PO)
Number of subjects: 80
Study 11404757 — intervention group
Group type: COMPARATOR
Intervention: Control (etched Lp = ELp)
Number of subjects: 80
Study 11404757 — intervention group
Group type: EXPERIMENTAL
Intervention: Impression Lp (ILp)
Number of subjects: 80
Study 9646215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrilon AR formula
Number of subjects: 24
Study 9646215 — intervention group
Group type: COMPARATOR
Intervention: Traditional thickened formula (5% rice flour)
Number of subjects: 24
Study 7962674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 15 mg
Number of subjects: 30
Study 7962674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 30
Study 7962674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 30
Study 7962674 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Number of subjects: 30
Study 7962674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2871378 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd-YAG laser photocoagulation
Number of subjects: 138
Study 2871378 — intervention group
Group type: COMPARATOR
Intervention: Control (no laser treatment)
Number of subjects: 138
Study 31603778 — intervention group
Group type: EXPERIMENTAL
Intervention: Source Density Apodisation (SDA)
Number of subjects: 0
Study 31603778 — intervention group
Group type: COMPARATOR
Intervention: Amplitude Apodisation (AmpA)
Number of subjects: 0
Study 31603778 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric SDA schemes
Number of subjects: 0
Study 31603778 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoothly varying spatial source density
Number of subjects: 0
Study 29300259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy for urgency-predominant urinary incontinence
Number of subjects: 640
Study 29300259 — intervention group
Group type: COMPARATOR
Intervention: Sleeping medications (used by 13% of participants 3 or more times per week)
Number of subjects: 640
Study 27017403 — intervention group
Group type: COMPARATOR
Intervention: Interferential current stimulation (IFCS) applied to submandibular and sublingual glands.
Number of subjects: 60
Study 27017403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFCS).
Number of subjects: 60
Study 25326710 — intervention group
Group type: EXPERIMENTAL
Intervention: All Children in Focus program (intervention group)
Number of subjects: 621
Study 25326710 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 621
Study 23685640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (n = 215), 0.5 mEq/kg/hr for the first hour and then 0.2 mmol/kg/hr for 23 hours
Number of subjects: 427
Study 23685640 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride infusion (n = 212)
Number of subjects: 427
Study 20941936 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation starting from the first postoperative day
Number of subjects: 60
Study 20941936 — intervention group
Group type: COMPARATOR
Intervention: Control group with rehabilitation starting 3 weeks after surgery
Number of subjects: 60
Study 18258532 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiclose‐T device
Number of subjects: 71
Study 18258532 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (Control)
Number of subjects: 71
Study 16365063 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g ALA/d from flaxseed oil capsules
Number of subjects: 56
Study 16365063 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo capsules
Number of subjects: 56
Study 16365063 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil and Olive oil
Number of subjects: 56
Study 12565986 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (r-HuEPO)
Number of subjects: 0
Study 12565986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11038148 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Iloprost (50-100 microgram twice a day)
Number of subjects: 802
Study 11038148 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Iloprost (150-200 microgram twice a day)
Number of subjects: 802
Study 11038148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study 9101938 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resections
Number of subjects: 39
Study 1358139 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0
Study 1358139 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 1358139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1358139 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 1358139 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical antihistamines
Number of subjects: 0
Study 6787910 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 20
Study 6787910 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 20
Study 30540660 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transversus abdominis plane block
Number of subjects: 107
Study 30540660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane block
Number of subjects: 107
Study 30540660 — intervention group
Group type: COMPARATOR
Intervention: No transversus abdominis plane block
Number of subjects: 107
Study 29197338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125%
Number of subjects: 78
Study 29197338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 78
Study 29197338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%
Number of subjects: 78
Study 29197338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 78
Study 29197338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 78
Study 29197338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 78
Study 29197338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (all concentrations)
Number of subjects: 78
Study 25360863 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the frontal sinus drainage pathway
Number of subjects: 30
Study 25360863 — intervention group
Group type: COMPARATOR
Intervention: Traditional frontal sinusotomy
Number of subjects: 30
Study 25360863 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation
Number of subjects: 30
Study 23643848 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitising paste containing 8% arginine and calcium carbonate (Ar‐Ca)
Number of subjects: 0
Study 23643848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumice treatment
Number of subjects: 0
Study 23643848 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 0
Study 21233431 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated behavioral intervention
Number of subjects: 436
Study 21233431 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 436
Study 19188061 — intervention group
Group type: EXPERIMENTAL
Intervention: Glufosfamide plus best supportive care (BSC)
Number of subjects: 303
Study 19188061 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 303
Study 17519792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 40